NCT04572295View on ClinicalTrials.gov

A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 9, 2020

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions

Breast Neoplasms

Interventions

DRUG

E7090

E7090 oral tablet.

DRUG

Fulvestrant

Fulvestrant intramuscular injection.

DRUG

Exemestane

Exemestane oral tablet.

Trial Locations (11)

Unknown

Eisai Trial Site 11, Nagoya

Eisai Trial Site 6, Kashiwa

Eisai Trial Site 9, Matsuyama

Eisai Trial Site 5, Yokohama

Eisai Trial Site 4, Sendai

Eisai Trial Site 7, Chuo-ku

Eisai Trial Site 10, Kitaadachi-gun

Eisai Trial Site 3, Chuo-ku

Eisai Trial Site 1, Koto-ku

Eisai Trial Site 2, Shinagawa-ku

Eisai Trial Site 8, Shinjuku-ku

All Listed Sponsors

lead

Eisai Co., Ltd.

INDUSTRY

NCT04572295 - A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter